加拿大trc标准品
共找到49条商品信息
保质期限：
产品认证：
注意事项：
上海 松江区
计量单位：
用途范围：
化学试剂 实验
广东省 广州市
1000.00/瓶
产品规格：
超纯、高纯
用途类别：
湖南省 长沙市
产品规格：
用途类别：
产品等级：
产品规格：
产品名称：
山东省 济宁市
包装规格：
产品性状：
白色晶体或粉末
生产厂家：
成都曼思特
贮存方法：
4℃冷藏、密封、避光
商品品牌：
商品型号：
产品名称：
欧夹竹桃苷乙
四川省 成都市
包装规格：
产品名称：
产品有效期：
含量（%）：
化学名称：
CAS号：50-81-7
江苏省 南京市
产品规格：
用途范围：
湖北省 武汉市
产品规格：
用途类别：
陕西省 宝鸡市
临床应用：
药理实验 合成底物
新奇创意项目：
检测方式：
江苏省 南京市
标准品对照品杂质
广东省 深圳市
≥98%(HPLC)
产品名称：
用于含量鉴定/测定药理实验
≤10（ppm）
江苏省 南京市
江苏省 南京市
产品规格：
PH标准试剂
产品规格：
PH标准试剂
100.00/毫克
产品规格：
用途范围：
≥98（％）
安徽省 合肥市
1000.00/瓶
用途类别：
产品规格：
陕西省 宝鸡市
河北省 石家庄市
150.00/毫克
江苏省 南京市
产品规格：
上海 浦东新区
本页是慧聪网为您提供的加拿大trc标准品最新供应商、经销商、厂家，包括加拿大trc标准品的参数、型号、图片、价格等信息，为您提供全面的加拿大trc标准品参考信息和在线洽谈的机会，找加拿大trc标准品供应信息尽在慧聪网。
加拿大trc标准品其他产品
加拿大trc标准品相关行业
加拿大trc标准品最新产品
按字母分类 ：
版权所有 慧聪网
通用网址：hc360
互联网药品信息服务资格证书：（京）－经营性－　海淀公安局网络备案编号：
Copyright?2000-. All Rights Reserved您的位置： &&
trans-Clopenthixol分析用标准品
起批量（1mg / 10mg）
￥1/1mg / 10mg
供货能力：
可销售总数量：
19 1mg / 10mg
最低订购量：
1 1mg / 10mg
建议零售价：
100元/1mg / 10mg
400-811-9081
联系我们时请说是从盖德化工网上看到的。
已通过企业实名备案
联&系&人：杨先生 销售
企业经济性质：股份有限公司
所&在&地&址：上海上海
详&细&地&址：上海浦东高青路4567弄1号楼303
上次登录时间：日
产品详细说明
英文名称：
trans-Clopenthixol
保存条件：
1) 【【咨询订购 400-811-9662 TRC试剂代理】】 货号：C587190; 【2】化学名： trans-Clopenthixol
上海子起生物科技是一家集贸易、科研、服务于一体的高科技企业，专业致力于化学分析、食品、环境、医药、化工、生命科学领域内的高品质分析、验证标准品、对照品、特种高分子材料、实验室设备和耗材等科研用品的集成供应商。公司有一批具有资深行业背景和丰富市场经验的专业人士组成，主要为企事业单位、科研机构、药物研发和生产企业等提供高品质化学品、仪器和耗材等；产品主要应用在食品、制药 、生物医药、精细化工、新能源、新材料、环境化学、现代农业、生物工程、生物化学等诸多领域。子起生物以完善和全面的产品线和专业的工作团队、贴心的服务、优质的产品、合理的价格以及顾问式的服务理念得到了众多客户的信任和一贯支持，并建立起中长期的合作关系.我们一直众多国际知名化学产品、医药中间体、检测机构保持良好而及时的沟通，建立了战略合作关系。积极将国际一流产品和技术引入国内，为国内客户以作工具和技术交流。
该公司相关产品
之前收到您的回复。
* 主要内容：价格要求：-
规格要求：-
产品数量：-
包装要求：-
您已经是盖德化工网会员？登录后自动填写以下表单内联系方式
您还不是盖德化工网会员？请填写您的联系方式,或点击这里
* 联系人：
* 邮&&箱：
公司名称：
* 联系电话：
k5qvczikhmecoatckvtvcmcupqbdea3maa6vilcqgqbdcdlwa42fayahhecdedbuk42aooqgmmht4azwarsvkykrgu
k5qvczikhmecoatckvtvcmcupqbdea3maa6vilcqgqbdcdlwa42fayahhecdedbuk42aooqgmmht4azwarsvkykrgu
trans-Clopenthixol分析用标准品相关产品报价
公司名称报价日期
VIP深圳振强生物技术有限公司
1元/10mg / 100mg
VIP上海子起生物科技有限公司
1元/1g / 10g
VIP上海子起生物科技有限公司
1元/10mg / 25mg
VIP上海子起生物科技有限公司
VIP深圳振强生物技术有限公司
VIP深圳振强生物技术有限公司
相关专题：
免责声明：
以上所展示的信息由企业自行提供，内容的真实性 、准确性和合法性由发布企业负责，盖德化工网对此不承担任何保证责任。 同时我们郑重提醒各位买/卖家，交易前 请详细核实对方身份，切勿随意打款或发货，谨防上当受骗。如发现虚假信息，请向盖德化工网举报。 。
总部电话：8
江苏办：025- 客服电话：1,6 展会合作：9
版权声 明&2017您现在的位置：>>> 正文
怎样在中国购买NIBSC标准品
&&&&& 英国国家生物制品检定所NIBSC是WHO的一个国际标准品供应中心实验室，它的核心工作是制备、保存和分发WHO用于检测全球生物制品质量的标准品。NIBSC制备的流感毒株和检测抗原、抗血清标准品，保障了各厂家顺利的研究和生产。NIBSC提供对投入英国市场的生物药品的独立测试，尤其是用于英国儿童免疫计划的疫苗；它同时也是欧盟控制药品进入欧盟市场的药品控制实验室(OMCL)。 如果出现不能满足药品存放要求或患者出现不良反应等问题，NIBSC 也可对已投入欧盟市场的产品进行检验。&&&&&& 深圳远扬化学技术有限公司代理英国NIBSC标准品（WHO标准品），价格优惠，质量保证，更多公司资料及NIBSC产品资料，欢迎进入我司展台进行查询。&&&&&& 除自主品牌杂质对照品外，我司还代理英国NIBSC标准品，美国剑桥CIL同位素标准品，美国NIST标准物质，欧洲标准局IRMM标准物质，加拿大TRC标准品，TLC标准品，MOLCAN标准品，NRC标准品等，欢迎洽谈。&01/455&Meningococcal serogroup W polysaccharide03/104-047&HTLV-32 (antibody) Monitor Sample95/637&Interleukin-98 (Human, rDNA derived)13/170&C-Peptide, Human. 25st International Standard.13/206&Influenza Antigen B/Massachusetts/02/2084 (Egg derived)03/104-022&HTLV-7 (antibody) Monitor Sample12/B623-021&QCRFLUAH1N1QC1-Influenza AH1N1 QC1901/477&Meningococcal serogroup W polysaccharide03/104-123&HTLV-108 (antibody) Monitor Sample10/179&Reteplase Reference Material13/267&Polio Anti Sabin type 50 (inactivated) Serum07/327&BCG Vaccine of Russian BCG-I sub-strain(54st WHO Reference Reagent)95/608&Interleukin-69 (Human, rDNA derived)13/225&Polio Anti Sabin type 8 (inactivated) Serum13/149&C-Peptide, Human. 4st International Standard.03/104-114&HTLV-99 (antibody) Monitor Sample07/303&BCG Vaccine of Russian BCG-I sub-strain(30st WHO Reference Reagent)07/328&BCG Vaccine of Russian BCG-I sub-strain(55st WHO Reference Reagent)10/152&Reteplase Reference Material12/B623-065&QCRFLUAH1N1QC1-Influenza AH1N1 QC6395/625&Interleukin-86 (Human, rDNA derived)13/302&Polio Anti Sabin type 85 (inactivated) Serum13/237&Polio Anti Sabin type 20 (inactivated) Serum01/435&Meningococcal serogroup W polysaccharide12/B623-097&QCRFLUAH1N1QC1-Influenza AH1N1 QC9513/269&Polio Anti Sabin type 52 (inactivated) Serum12/B623-055&QCRFLUAH1N1QC1-Influenza AH1N1 QC5303/104-103&HTLV-88 (antibody) Monitor Sample03/104-073&HTLV-58 (antibody) Monitor Sample07/350&BCG Vaccine of Russian BCG-I sub-strain(77st WHO Reference Reagent)10/105&Reteplase Reference Material01/431&Meningococcal serogroup W polysaccharide10/106&Reteplase Reference Material95/654&Interleukin-115 (Human, rDNA derived)01/428&Meningococcal serogroup W polysaccharide01/484&Meningococcal serogroup W polysaccharide03/104-019&HTLV-4 (antibody) Monitor Sample12/B623-006&QCRFLUAH1N1QC1-Influenza AH1N1 QC413/210&Influenza Antigen B/Massachusetts/02/2088 (Egg derived)13/192&C-Peptide, Human. 47st International Standard.10/160&Reteplase Reference Material07/326&BCG Vaccine of Russian BCG-I sub-strain(53st WHO Reference Reagent)12/B623-087&QCRFLUAH1N1QC1-Influenza AH1N1 QC8503/104-111&HTLV-96 (antibody) Monitor Sample95/595&Interleukin-56 (Human, rDNA derived)13/204&C-Peptide, Human. 59st International Standard.12/B623-108&QCRFLUAH1N1QC1-Influenza AH1N1 QC10610/185&Reteplase Reference Material12/B623-064&QCRFLUAH1N1QC1-Influenza AH1N1 QC6212/B623-068&QCRFLUAH1N1QC1-Influenza AH1N1 QC6613/222&Polio Anti Sabin type 5 (inactivated) Serum13/148&C-Peptide, Human. 3st International Standard.13/315&Polio Anti Sabin type 98 (inactivated) Serum12/B623-092&QCRFLUAH1N1QC1-Influenza AH1N1 QC9003/104-092&HTLV-77 (antibody) Monitor Sample13/157&Influenza Antigen B/Massachusetts/02/2035 (Egg derived)03/104-052&HTLV-37 (antibody) Monitor Sample03/104-042&HTLV-27 (antibody) Monitor Sample13/314&Polio Anti Sabin type 97 (inactivated) Serum10/145&Reteplase Reference Material12/B623-031&QCRFLUAH1N1QC1-Influenza AH1N1 QC2910/205&Reteplase Reference Material12/B623-099&QCRFLUAH1N1QC1-Influenza AH1N1 QC9713/220&C-Peptide, Human. 75st International Standard.13/174&C-Peptide, Human. 29st International Standard.13/157&C-Peptide, Human. 12st International Standard.10/156&Reteplase Reference Material13/231&Influenza Antigen B/Massachusetts/02/2109 (Egg derived)10/111&Reteplase Reference Material95/578&Interleukin-39 (Human, rDNA derived)12/B623-076&QCRFLUAH1N1QC1-Influenza AH1N1 QC7413/159&Influenza Antigen B/Massachusetts/02/2037 (Egg derived)95/631&Interleukin-92 (Human, rDNA derived)03/104-016&HTLV-1 (antibody) Monitor Sample13/146&C-Peptide, Human. 1st International Standard.95/612&Interleukin-73 (Human, rDNA derived)13/214&C-Peptide, Human. 69st International Standard.95/616&Interleukin-77 (Human, rDNA derived)03/104-090&HTLV-75 (antibody) Monitor Sample13/166&C-Peptide, Human. 21st International Standard.07/340&BCG Vaccine of Russian BCG-I sub-strain(67st WHO Reference Reagent)95/615&Interleukin-76 (Human, rDNA derived)10/188&Reteplase Reference Material13/148&Influenza Antigen B/Massachusetts/02/2026 (Egg derived)13/194&Influenza Antigen B/Massachusetts/02/2072 (Egg derived)03/104-098&HTLV-83 (antibody) Monitor Sample13/232&Polio Anti Sabin type 15 (inactivated) Serum13/200&Influenza Antigen B/Massachusetts/02/2078 (Egg derived)07/365&BCG Vaccine of Russian BCG-I sub-strain(92st WHO Reference Reagent)95/609&Interleukin-70 (Human, rDNA derived)13/155&Influenza Antigen B/Massachusetts/02/2033 (Egg derived)12/B623-067&QCRFLUAH1N1QC1-Influenza AH1N1 QC6501/464&Meningococcal serogroup W polysaccharide01/498&Meningococcal serogroup W polysaccharide03/104-113&HTLV-98 (antibody) Monitor Sample10/167&Reteplase Reference Material07/277&BCG Vaccine of Russian BCG-I sub-strain(4st WHO Reference Reagent)13/262&Polio Anti Sabin type 45 (inactivated) Serum13/237&C-Peptide, Human. 92st International Standard.03/104-029&HTLV-14 (antibody) Monitor Sample01/447&Meningococcal serogroup W polysaccharide03/104-059&HTLV-44 (antibody) Monitor Sample13/293&Polio Anti Sabin type 76 (inactivated) Serum95/611&Interleukin-72 (Human, rDNA derived)01/458&Meningococcal serogroup W polysaccharide13/254&Polio Anti Sabin type 37 (inactivated) Serum07/286&BCG Vaccine of Russian BCG-I sub-strain(13st WHO Reference Reagent)07/295&BCG Vaccine of Russian BCG-I sub-strain(22st WHO Reference Reagent)13/188&C-Peptide, Human. 43st International Standard.12/B623-037&QCRFLUAH1N1QC1-Influenza AH1N1 QC3513/201&C-Peptide, Human. 56st International Standard.13/198&Influenza Antigen B/Massachusetts/02/2076 (Egg derived)10/119&Reteplase Reference Material95/620&Interleukin-81 (Human, rDNA derived)10/178&Reteplase Reference Material12/B623-029&QCRFLUAH1N1QC1-Influenza AH1N1 QC2713/234&C-Peptide, Human. 89st International Standard.13/203&C-Peptide, Human. 58st International Standard.01/459&Meningococcal serogroup W polysaccharide13/200&C-Peptide, Human. 55st International Standard.07/334&BCG Vaccine of Russian BCG-I sub-strain(61st WHO Reference Reagent)95/563&Interleukin-24 (Human, rDNA derived)13/325&Polio Anti Sabin type 108 (inactivated) Serum07/371&BCG Vaccine of Russian BCG-I sub-strain(98st WHO Reference Reagent)10/193&Reteplase Reference Material13/165&C-Peptide, Human. 20st International Standard.95/577&Interleukin-38 (Human, rDNA derived)01/492&Meningococcal serogroup W polysaccharide03/104-116&HTLV-101 (antibody) Monitor Sample10/157&Reteplase Reference Material12/B623-079&QCRFLUAH1N1QC1-Influenza AH1N1 QC7713/195&C-Peptide, Human. 50st International Standard.95/641&Interleukin-102 (Human, rDNA derived)10/130&Reteplase Reference Material10/133&Reteplase Reference Material13/274&Polio Anti Sabin type 57 (inactivated) Serum07/361&BCG Vaccine of Russian BCG-I sub-strain(88st WHO Reference Reagent)95/600&Interleukin-61 (Human, rDNA derived)13/268&Polio Anti Sabin type 51 (inactivated) Serum03/104-089&HTLV-74 (antibody) Monitor Sample01/530&Meningococcal serogroup W polysaccharide13/178&Influenza Antigen B/Massachusetts/02/2056 (Egg derived)01/516&Meningococcal serogroup W polysaccharide10/143&Reteplase Reference Material95/597&Interleukin-58 (Human, rDNA derived)10/104&Reteplase Reference Material07/364&BCG Vaccine of Russian BCG-I sub-strain(91st WHO Reference Reagent)95/623&Interleukin-84 (Human, rDNA derived)13/247&C-Peptide, Human. 102st International Standard.07/305&BCG Vaccine of Russian BCG-I sub-strain(32st WHO Reference Reagent)13/193&Influenza Antigen B/Massachusetts/02/2071 (Egg derived)12/B623-033&QCRFLUAH1N1QC1-Influenza AH1N1 QC3101/441&Meningococcal serogroup W polysaccharide01/522&Meningococcal serogroup W polysaccharide10/211&Reteplase Reference Material13/224&C-Peptide, Human. 79st International Standard.95/659&Interleukin-120 (Human, rDNA derived)13/248&Polio Anti Sabin type 31 (inactivated) Serum10/142&Reteplase Reference Material10/183&Reteplase Reference Material01/438&Meningococcal serogroup W polysaccharide03/104-101&HTLV-86 (antibody) Monitor Sample10/141&Reteplase Reference Material13/186&C-Peptide, Human. 41st International Standard.07/367&BCG Vaccine of Russian BCG-I sub-strain(94st WHO Reference Reagent)95/640&Interleukin-101 (Human, rDNA derived)13/281&Polio Anti Sabin type 64 (inactivated) Serum03/104-049&HTLV-34 (antibody) Monitor Sample13/266&Polio Anti Sabin type 49 (inactivated) Serum10/189&Reteplase Reference Material13/307&Polio Anti Sabin type 90 (inactivated) Serum10/129&Reteplase Reference Material01/491&Meningococcal serogroup W polysaccharide01/453&Meningococcal serogroup W polysaccharide95/590&Interleukin-51 (Human, rDNA derived)12/B623-060&QCRFLUAH1N1QC1-Influenza AH1N1 QC5813/154&Influenza Antigen B/Massachusetts/02/2032 (Egg derived)01/532&Meningococcal serogroup W polysaccharide07/297&BCG Vaccine of Russian BCG-I sub-strain(24st WHO Reference Reagent)01/507&Meningococcal serogroup W polysaccharide13/309&Polio Anti Sabin type 92 (inactivated) Serum95/586&Interleukin-47 (Human, rDNA derived)03/104-078&HTLV-63 (antibody) Monitor Sample03/104-051&HTLV-36 (antibody) Monitor Sample13/240&Polio Anti Sabin type 23 (inactivated) Serum95/593&Interleukin-54 (Human, rDNA derived)13/238&C-Peptide, Human. 93st International Standard.10/138&Reteplase Reference Material13/187&C-Peptide, Human. 42st International Standard.95/589&Interleukin-50 (Human, rDNA derived)13/319&Polio Anti Sabin type 102 (inactivated) Serum10/169&Reteplase Reference Material01/480&Meningococcal serogroup W polysaccharide95/556&Interleukin-17 (Human, rDNA derived)10/184&Reteplase Reference Material13/177&Influenza Antigen B/Massachusetts/02/2055 (Egg derived)07/315&BCG Vaccine of Russian BCG-I sub-strain(42st WHO Reference Reagent)03/104-064&HTLV-49 (antibody) Monitor Sample13/280&Polio Anti Sabin type 63 (inactivated) Serum12/B623-069&QCRFLUAH1N1QC1-Influenza AH1N1 QC6713/264&Polio Anti Sabin type 47 (inactivated) Serum13/270&Polio Anti Sabin type 53 (inactivated) Serum13/230&C-Peptide, Human. 85st International Standard.10/151&Reteplase Reference Material13/231&C-Peptide, Human. 86st International Standard.01/509&Meningococcal serogroup W polysaccharide10/166&Reteplase Reference Material01/528&Meningococcal serogroup W polysaccharide03/104-062&HTLV-47 (antibody) Monitor Sample03/104-118&HTLV-103 (antibody) Monitor Sample01/439&Meningococcal serogroup W polysaccharide13/219&C-Peptide, Human. 74st International Standard.07/322&BCG Vaccine of Russian BCG-I sub-strain(49st WHO Reference Reagent)10/120&Reteplase Reference Material12/B623-051&QCRFLUAH1N1QC1-Influenza AH1N1 QC4913/221&Influenza Antigen B/Massachusetts/02/2099 (Egg derived)13/140&Influenza Antigen B/Massachusetts/02/2018 (Egg derived)07/324&BCG Vaccine of Russian BCG-I sub-strain(51st WHO Reference Reagent)10/131&Reteplase Reference Material10/112&Reteplase Reference Material13/253&C-Peptide, Human. 108st International Standard.13/237&Influenza Antigen B/Massachusetts/02/2115 (Egg derived)03/104-021&HTLV-6 (antibody) Monitor Sample01/440&Meningococcal serogroup W polysaccharide07/333&BCG Vaccine of Russian BCG-I sub-strain(60st WHO Reference Reagent)95/633&Interleukin-94 (Human, rDNA derived)01/534&Meningococcal serogroup W polysaccharide03/104-041&HTLV-26 (antibody) Monitor Sample03/104-035&HTLV-20 (antibody) Monitor Sample10/132&Reteplase Reference Material13/191&C-Peptide, Human. 46st International Standard.13/228&Polio Anti Sabin type 11 (inactivated) Serum13/245&C-Peptide, Human. 100st International Standard.12/B623-027&QCRFLUAH1N1QC1-Influenza AH1N1 QC2512/B623-043&QCRFLUAH1N1QC1-Influenza AH1N1 QC4110/201&Reteplase Reference Material07/335&BCG Vaccine of Russian BCG-I sub-strain(62st WHO Reference Reagent)13/228&Influenza Antigen B/Massachusetts/02/2106 (Egg derived)12/B623-080&QCRFLUAH1N1QC1-Influenza AH1N1 QC7810/186&Reteplase Reference Material07/355&BCG Vaccine of Russian BCG-I sub-strain(82st WHO Reference Reagent)13/168&C-Peptide, Human. 23st International Standard.07/338&BCG Vaccine of Russian BCG-I sub-strain(65st WHO Reference Reagent)01/488&Meningococcal serogroup W polysaccharide07/282&BCG Vaccine of Russian BCG-I sub-strain(9st WHO Reference Reagent)12/B623-036&QCRFLUAH1N1QC1-Influenza AH1N1 QC3495/621&Interleukin-82 (Human, rDNA derived)95/579&Interleukin-40 (Human, rDNA derived)13/312&Polio Anti Sabin type 95 (inactivated) Serum01/510&Meningococcal serogroup W polysaccharide13/179&Influenza Antigen B/Massachusetts/02/2057 (Egg derived)07/314&BCG Vaccine of Russian BCG-I sub-strain(41st WHO Reference Reagent)12/B623-104&QCRFLUAH1N1QC1-Influenza AH1N1 QC10203/104-077&HTLV-62 (antibody) Monitor Sample13/198&C-Peptide, Human. 53st International Standard.95/602&Interleukin-63 (Human, rDNA derived)03/104-063&HTLV-48 (antibody) Monitor Sample07/284&BCG Vaccine of Russian BCG-I sub-strain(11st WHO Reference Reagent)07/373&BCG Vaccine of Russian BCG-I sub-strain(100st WHO Reference Reagent)13/308&Polio Anti Sabin type 91 (inactivated) Serum13/286&Polio Anti Sabin type 69 (inactivated) Serum10/191&Reteplase Reference Material13/240&C-Peptide, Human. 95st International Standard.13/136&Influenza Antigen B/Massachusetts/02/2014 (Egg derived)10/154&Reteplase Reference Material95/629&Interleukin-90 (Human, rDNA derived)13/183&C-Peptide, Human. 38st International Standard.13/318&Polio Anti Sabin type 101 (inactivated) Serum13/147&Influenza Antigen B/Massachusetts/02/2025 (Egg derived)07/357&BCG Vaccine of Russian BCG-I sub-strain(84st WHO Reference Reagent)95/587&Interleukin-48 (Human, rDNA derived)03/104-032&HTLV-17 (antibody) Monitor Sample13/292&Polio Anti Sabin type 75 (inactivated) Serum13/272&Polio Anti Sabin type 55 (inactivated) Serum01/500&Meningococcal serogroup W polysaccharide10/115&Reteplase Reference Material03/104-121&HTLV-106 (antibody) Monitor Sample95/555&Interleukin-16 (Human, rDNA derived)12/B623-007&QCRFLUAH1N1QC1-Influenza AH1N1 QC503/104-037&HTLV-22 (antibody) Monitor Sample13/251&Polio Anti Sabin type 34 (inactivated) Serum03/104-046&HTLV-31 (antibody) Monitor Sample03/104-070&HTLV-55 (antibody) Monitor Sample12/B623-085&QCRFLUAH1N1QC1-Influenza AH1N1 QC8310/134&Reteplase Reference Material01/475&Meningococcal serogroup W polysaccharide10/147&Reteplase Reference Material13/150&C-Peptide, Human. 5st International Standard.10/165&Reteplase Reference Material01/445&Meningococcal serogroup W polysaccharide13/164&Influenza Antigen B/Massachusetts/02/2042 (Egg derived)01/494&Meningococcal serogroup W polysaccharide13/298&Polio Anti Sabin type 81 (inactivated) Serum13/183&Influenza Antigen B/Massachusetts/02/2061 (Egg derived)13/283&Polio Anti Sabin type 66 (inactivated) Serum12/B623-045&QCRFLUAH1N1QC1-Influenza AH1N1 QC4303/104-028&HTLV-13 (antibody) Monitor Sample07/347&BCG Vaccine of Russian BCG-I sub-strain(74st WHO Reference Reagent)01/508&Meningococcal serogroup W polysaccharide10/122&Reteplase Reference Material95/630&Interleukin-91 (Human, rDNA derived)01/511&Meningococcal serogroup W polysaccharide12/B623-109&QCRFLUAH1N1QC1-Influenza AH1N1 QC10795/585&Interleukin-46 (Human, rDNA derived)13/236&Influenza Antigen B/Massachusetts/02/2114 (Egg derived)07/280&BCG Vaccine of Russian BCG-I sub-strain(7st WHO Reference Reagent)13/289&Polio Anti Sabin type 72 (inactivated) Serum07/352&BCG Vaccine of Russian BCG-I sub-strain(79st WHO Reference Reagent)13/134&Influenza Antigen B/Massachusetts/02/2012 (Egg derived)13/138&Influenza Antigen B/Massachusetts/02/2016 (Egg derived)13/241&C-Peptide, Human. 96st International Standard.13/223&Polio Anti Sabin type 6 (inactivated) Serum10/195&Reteplase Reference Material01/429&Meningococcal serogroup W polysaccharide12/B623-020&QCRFLUAH1N1QC1-Influenza AH1N1 QC1812/B623-017&QCRFLUAH1N1QC1-Influenza AH1N1 QC1513/261&Polio Anti Sabin type 44 (inactivated) Serum03/104-053&HTLV-38 (antibody) Monitor Sample13/250&C-Peptide, Human. 105st International Standard.13/197&Influenza Antigen B/Massachusetts/02/2075 (Egg derived)95/632&Interleukin-93 (Human, rDNA derived)12/B623-004&QCRFLUAH1N1QC1-Influenza AH1N1 QC210/196&Reteplase Reference Material12/B623-009&QCRFLUAH1N1QC1-Influenza AH1N1 QC701/521&Meningococcal serogroup W polysaccharide13/247&Polio Anti Sabin type 30 (inactivated) Serum03/104-069&HTLV-54 (antibody) Monitor Sample95/603&Interleukin-64 (Human, rDNA derived)13/301&Polio Anti Sabin type 84 (inactivated) Serum13/236&C-Peptide, Human. 91st International Standard.03/104-122&HTLV-107 (antibody) Monitor Sample07/349&BCG Vaccine of Russian BCG-I sub-strain(76st WHO Reference Reagent)12/B623-032&QCRFLUAH1N1QC1-Influenza AH1N1 QC3012/B623-039&QCRFLUAH1N1QC1-Influenza AH1N1 QC3713/295&Polio Anti Sabin type 78 (inactivated) Serum07/320&BCG Vaccine of Russian BCG-I sub-strain(47st WHO Reference Reagent)03/104-074&HTLV-59 (antibody) Monitor Sample01/430&Meningococcal serogroup W polysaccharide13/189&Influenza Antigen B/Massachusetts/02/2067 (Egg derived)03/104-066&HTLV-51 (antibody) Monitor Sample07/331&BCG Vaccine of Russian BCG-I sub-strain(58st WHO Reference Reagent)13/156&Influenza Antigen B/Massachusetts/02/2034 (Egg derived)01/473&Meningococcal serogroup W polysaccharide13/243&Polio Anti Sabin type 26 (inactivated) Serum13/214&Influenza Antigen B/Massachusetts/02/2092 (Egg derived)03/104-115&HTLV-100 (antibody) Monitor Sample01/535&Meningococcal serogroup W polysaccharide13/223&Influenza Antigen B/Massachusetts/02/2101 (Egg derived)13/188&Influenza Antigen B/Massachusetts/02/2066 (Egg derived)03/104-094&HTLV-79 (antibody) Monitor Sample12/B623-075&QCRFLUAH1N1QC1-Influenza AH1N1 QC7310/125&Reteplase Reference Material13/216&C-Peptide, Human. 71st International Standard.13/189&C-Peptide, Human. 44st International Standard.07/325&BCG Vaccine of Russian BCG-I sub-strain(52st WHO Reference Reagent)01/449&Meningococcal serogroup W polysaccharide10/153&Reteplase Reference Material95/610&Interleukin-71 (Human, rDNA derived)07/300&BCG Vaccine of Russian BCG-I sub-strain(27st WHO Reference Reagent)10/136&Reteplase Reference Material13/311&Polio Anti Sabin type 94 (inactivated) Serum10/158&Reteplase Reference Material95/591&Interleukin-52 (Human, rDNA derived)12/B623-078&QCRFLUAH1N1QC1-Influenza AH1N1 QC7613/207&Influenza Antigen B/Massachusetts/02/2085 (Egg derived)01/467&Meningococcal serogroup W polysaccharide12/B623-024&QCRFLUAH1N1QC1-Influenza AH1N1 QC2201/456&Meningococcal serogroup W polysaccharide07/358&BCG Vaccine of Russian BCG-I sub-strain(85st WHO Reference Reagent)07/336&BCG Vaccine of Russian BCG-I sub-strain(63st WHO Reference Reagent)10/180&Reteplase Reference Material03/104-044&HTLV-29 (antibody) Monitor Sample13/175&C-Peptide, Human. 30st International Standard.13/158&C-Peptide, Human. 13st International Standard.13/224&Influenza Antigen B/Massachusetts/02/2102 (Egg derived)95/624&Interleukin-85 (Human, rDNA derived)13/137&Influenza Antigen B/Massachusetts/02/2015 (Egg derived)10/198&Reteplase Reference Material13/265&Polio Anti Sabin type 48 (inactivated) Serum07/380&BCG Vaccine of Russian BCG-I sub-strain(107st WHO Reference Reagent)07/278&BCG Vaccine of Russian BCG-I sub-strain(5st WHO Reference Reagent)13/180&Influenza Antigen B/Massachusetts/02/2058 (Egg derived)95/626&Interleukin-87 (Human, rDNA derived)12/B623-008&QCRFLUAH1N1QC1-Influenza AH1N1 QC695/635&Interleukin-96 (Human, rDNA derived)13/176&Influenza Antigen B/Massachusetts/02/2054 (Egg derived)13/187&Influenza Antigen B/Massachusetts/02/2065 (Egg derived)12/B623-019&QCRFLUAH1N1QC1-Influenza AH1N1 QC1701/468&Meningococcal serogroup W polysaccharide10/199&Reteplase Reference Material13/231&Polio Anti Sabin type 14 (inactivated) Serum12/B623-012&QCRFLUAH1N1QC1-Influenza AH1N1 QC1003/104-119&HTLV-104 (antibody) Monitor Sample13/290&Polio Anti Sabin type 73 (inactivated) Serum13/167&Influenza Antigen B/Massachusetts/02/2045 (Egg derived)13/171&C-Peptide, Human. 26st International Standard.03/104-099&HTLV-84 (antibody) Monitor Sample07/370&BCG Vaccine of Russian BCG-I sub-strain(97st WHO Reference Reagent)12/B623-077&QCRFLUAH1N1QC1-Influenza AH1N1 QC7503/104-055&HTLV-40 (antibody) Monitor Sample01/499&Meningococcal serogroup W polysaccharide95/583&Interleukin-44 (Human, rDNA derived)13/161&C-Peptide, Human. 16st International Standard.12/B623-042&QCRFLUAH1N1QC1-Influenza AH1N1 QC4013/246&C-Peptide, Human. 101st International Standard.95/601&Interleukin-62 (Human, rDNA derived)03/104-060&HTLV-45 (antibody) Monitor Sample12/B623-066&QCRFLUAH1N1QC1-Influenza AH1N1 QC6412/B623-038&QCRFLUAH1N1QC1-Influenza AH1N1 QC3610/209&Reteplase Reference Material13/181&Influenza Antigen B/Massachusetts/02/2059 (Egg derived)95/562&Interleukin-23 (Human, rDNA derived)03/104-030&HTLV-15 (antibody) Monitor Sample10/200&Reteplase Reference Material03/104-068&HTLV-53 (antibody) Monitor Sample07/374&BCG Vaccine of Russian BCG-I sub-strain(101st WHO Reference Reagent)95/560&Interleukin-21 (Human, rDNA derived)03/104-108&HTLV-93 (antibody) Monitor Sample01/517&Meningococcal serogroup W polysaccharide13/212&Influenza Antigen B/Massachusetts/02/2090 (Egg derived)13/238&Influenza Antigen B/Massachusetts/02/2116 (Egg derived)13/239&C-Peptide, Human. 94st International Standard.03/104-082&HTLV-67 (antibody) Monitor Sample13/255&Polio Anti Sabin type 38 (inactivated) Serum03/104-027&HTLV-12 (antibody) Monitor Sample07/376&BCG Vaccine of Russian BCG-I sub-strain(103st WHO Reference Reagent)03/104-087&HTLV-72 (antibody) Monitor Sample03/104-017&HTLV-2 (antibody) Monitor Sample01/434&Meningococcal serogroup W polysaccharide13/236&Polio Anti Sabin type 19 (inactivated) Serum13/222&Influenza Antigen B/Massachusetts/02/2100 (Egg derived)10/155&Reteplase Reference Material12/B623-103&QCRFLUAH1N1QC1-Influenza AH1N1 QC10103/104-085&HTLV-70 (antibody) Monitor Sample01/465&Meningococcal serogroup W polysaccharide13/224&Polio Anti Sabin type 7 (inactivated) Serum12/B623-081&QCRFLUAH1N1QC1-Influenza AH1N1 QC7910/124&Reteplase Reference Material12/B623-072&QCRFLUAH1N1QC1-Influenza AH1N1 QC7013/206&C-Peptide, Human. 61st International Standard.13/207&C-Peptide, Human. 62st International Standard.13/227&Polio Anti Sabin type 10 (inactivated) Serum13/158&Influenza Antigen B/Massachusetts/02/2036 (Egg derived)13/155&C-Peptide, Human. 10st International Standard.95/649&Interleukin-110 (Human, rDNA derived)01/479&Meningococcal serogroup W polysaccharide03/104-109&HTLV-94 (antibody) Monitor Sample95/638&Interleukin-99 (Human, rDNA derived)07/369&BCG Vaccine of Russian BCG-I sub-strain(96st WHO Reference Reagent)10/182&Reteplase Reference Material95/584&Interleukin-45 (Human, rDNA derived)12/B623-095&QCRFLUAH1N1QC1-Influenza AH1N1 QC9313/160&C-Peptide, Human. 15st International Standard.07/381&BCG Vaccine of Russian BCG-I sub-strain(108st WHO Reference Reagent)01/519&Meningococcal serogroup W polysaccharide10/181&Reteplase Reference Material13/227&Influenza Antigen B/Massachusetts/02/2105 (Egg derived)95/568&Interleukin-29 (Human, rDNA derived)13/322&Polio Anti Sabin type 105 (inactivated) Serum13/241&Influenza Antigen B/Massachusetts/02/2119 (Egg derived)01/437&Meningococcal serogroup W polysaccharide03/104-057&HTLV-42 (antibody) Monitor Sample95/613&Interleukin-74 (Human, rDNA derived)13/299&Polio Anti Sabin type 82 (inactivated) Serum13/251&C-Peptide, Human. 106st International Standard.13/243&C-Peptide, Human. 98st International Standard.13/213&Influenza Antigen B/Massachusetts/02/2091 (Egg derived)03/104-039&HTLV-24 (antibody) Monitor Sample13/305&Polio Anti Sabin type 88 (inactivated) Serum13/197&C-Peptide, Human. 52st International Standard.07/351&BCG Vaccine of Russian BCG-I sub-strain(78st WHO Reference Reagent)10/177&Reteplase Reference Material95/645&Interleukin-106 (Human, rDNA derived)12/B623-052&QCRFLUAH1N1QC1-Influenza AH1N1 QC5012/B623-101&QCRFLUAH1N1QC1-Influenza AH1N1 QC9995/567&Interleukin-28 (Human, rDNA derived)13/320&Polio Anti Sabin type 103 (inactivated) Serum13/139&Influenza Antigen B/Massachusetts/02/2017 (Egg derived)95/559&Interleukin-20 (Human, rDNA derived)10/206&Reteplase Reference Material13/226&Polio Anti Sabin type 9 (inactivated) Serum07/299&BCG Vaccine of Russian BCG-I sub-strain(26st WHO Reference Reagent)95/592&Interleukin-53 (Human, rDNA derived)12/B623-096&QCRFLUAH1N1QC1-Influenza AH1N1 QC9401/474&Meningococcal serogroup W polysaccharide01/463&Meningococcal serogroup W polysaccharide07/275&BCG Vaccine of Russian BCG-I sub-strain(2st WHO Reference Reagent)13/177&C-Peptide, Human. 32st International Standard.12/B623-041&QCRFLUAH1N1QC1-Influenza AH1N1 QC3907/288&BCG Vaccine of Russian BCG-I sub-strain(15st WHO Reference Reagent)12/B623-025&QCRFLUAH1N1QC1-Influenza AH1N1 QC2313/178&C-Peptide, Human. 33st International Standard.95/618&Interleukin-79 (Human, rDNA derived)13/222&C-Peptide, Human. 77st International Standard.&
关注本网官方微信 随时阅权威资讯
全年征稿 / 资讯合作
联系邮箱：
版权与免责声明
凡本网注明“来源：中国化工仪器网”的所有作品，版权均属于中国化工仪器网，转载请必须注明中国化工仪器网，，违反者本网将追究相关法律责任。
本网转载并注明自其它来源的作品，目的在于传递更多信息，并不代表本网赞同其观点或证实其内容的真实性，不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时，必须保留本网注明的作品来源，并自负版权等法律责任。
如涉及作品内容、版权等问题，请在作品发表之日起一周内与本网联系，否则视为放弃相关权利。
　　经国务院签批，2月23日发布《“十三五”国
2月里，国内仪器仪表行业取得了多项突破性的进展，国产仪器仪表的崛起势头十分强劲，让
“中国(广州)分析测试论坛”于-23日在广州召开。
　　2月14日晚9时30分，河南洛阳市栾川县龙宇钼业有限公司尾矿库6号溢流井发生坍塌，造